Author

H. D. Lim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1 Organism:rat· 1 Approach:statistical model· 1

Frequent Co-Authors

J. R. Lane· 2 shared L. Shi· 2 shared A. E. Dulcey· 1 shared A. M. Abramyan· 1 shared A. N. Nilson· 1 shared D. R. Sibley· 1 shared J. A. Javitch· 1 shared J. H. Woods· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

J. R. Lane

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification and Characterization of ML321: a Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity

R. B. Free, A. N. Nilson, N. M. Boldizsar, T. Doyle, R. M. Rodriguiz, V. M. Pogorelov, M. Machino, K. H. Lee, J. W. Bertz, J. Xu, H. D. Lim, A. E. Dulcey, R. H. Mach, J. H. Woods, J. R. Lane, , D. R. Sibley

This paper develops ML321, a highly selective D2 dopamine receptor antagonist, showing efficacy in animal models predictive of atypical antipsychotic activity with fewer side effects.

bioRxiv · Nov 14, 2022Pharmacology & Toxicology

Distinct antagonist-bound inactive states underlie the divergence in the structures of the dopamine D2 and D3 receptors

J. R. Lane, A. M. Abramyan, R. K. Verma, H. D. Lim, J. A. Javitch, L. Shi

The paper identifies distinct antagonist-bound inactive states in dopamine D2 and D3 receptors, showing conformational diversity with implications for drug discovery.

bioRxiv · May 17, 2019 · PreprintBiophysics